Tafasitamab and lenalidomide in large B-cell lymphoma: real-world outcomes in a multicenter retrospective study

In this real-world evaluation of tafasitamab-lenalidomide (TL) in relapsed or refractory LBCL, patients receiving TL had higher rates of comorbidities and high-risk disease characteristics, and substantially lower progression-free survival and overall survival, compared with the L-MIND registration...

Full description

Saved in:
Bibliographic Details
Published in:Blood 2023-12, Vol.142 (26), p.2327-2331
Main Authors: Qualls, David A., Lambert, Nicholas, Caimi, Paolo F., Merrill, Mwanasha, Pullarkat, Priyanka, Godby, Richard C., Bond, David A., Wehmeyer, Graham T., Romancik, Jason, Amoozgar, Behzad, Leslie, Lori, Nastoupil, Loretta J., Crombie, Jennifer L., Abramson, Jeremy S., Khurana, Arushi, Nowakowski, Grzegorz S., Maddocks, Kami, Rutherford, Sarah C., Kahl, Brad, Okwali, Michelle, Buege, Michael J., Seshan, Venkatraman, Batlevi, Connie L., Salles, Gilles
Format: Article
Language:English
Subjects:
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Humans
Lenalidomide - therapeutic use
Letter to Blood
Lymphoma, Large B-Cell, Diffuse - drug therapy
Retrospective Studies
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In this real-world evaluation of tafasitamab-lenalidomide (TL) in relapsed or refractory LBCL, patients receiving TL had higher rates of comorbidities and high-risk disease characteristics, and substantially lower progression-free survival and overall survival, compared with the L-MIND registration clinical trial for TL.
ISSN:0006-4971
1528-0020
1528-0020
DOI:10.1182/blood.2023021274